The DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients
Open accessAbstract
Experimental fibroblast growth factor 21 (FGF21) analogs can improve lipid profiles in patients with metabolic diseases. However, their effects on markers of insulin sensitivity appear to be minimal, potentially because of insufficient exposure. Systemic drug levels vary from sub-pharmacological to demonstrating pharmacodynamic effects but with dose-limiting adverse events. Here we report results from a phase 1 multiple ascending dose study of AKR-001, an Fc-FGF21 fusion protein engineered for sustained systemic pharmacologic exposure, in individuals with type 2 diabetes. With a half-life of 3-3.5 days, the peak-to-trough ratio under steady-state conditions is approximately 2 following QW dosing. AKR-001 appears to demonstrate pharmacodynamic effects on serum markers of insulin sensitivity and acceptable tolerability up to and including 70 mg QW. Positive trends in lipoprotein profile, including triglycerides, non-high-density lipoprotein (non-HDL) cholesterol, HDL-C, and apolipoproteins B and C3 are consistent with other FGF21 analogs. AKR-001's clinical profile supports further evaluation as a treatment for metabolic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Administration of the FGF21 analogues AKR-001 (ref. 88) and pegbelfermin89 in humans with NASH results in marked absolute decreases in liver fat (up to 70%) and significant amelioration of liver fibrosis88,89.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [88]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“two other FGF21 analogues, AKR-001 (also known as efruxifermin)88 and pegbelfermin89,90, have not been found to significantly decrease body weight in people with obesity or type 2 diabetes.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [88]
The cited source says what the claim attributes to it.
In the citing paper
“most adverse effects associated with FGF21-analogue administration are gastrointestinal81,87,88.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [88]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PF-05231023 has been found to increase markers of bone turnover in humans81, whereas AKR-001 (ref. 88) and pegbelfermin89 have not.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“all analogues consistently have a pronounced ability to decrease plasma triglyceride levels, in many cases by as much as ~70% (refs. 81,87–91).”
From Metabolic messengers: FGF21 (2021) · cites this paper as [88]
In the citing paper
“some compounds do not significantly affect insulin sensitivity81, while others significantly increase insulin sensitivity in people with type 2 diabetes87,88.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [88]
In the citing paper
“the magnitude of the glucose-lowering effects of FGF21 analogues is clearly lower in humans than rodents81,87–91, perhaps because of differences in brown adipose tissue metabolism between species65.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [88]
In the citing paper
“Pharmacological administration of FGF21 or FGF21 analogues exerts lipid-lowering effects through accelerated lipoprotein catabolism108, suppression of postprandial lipolysis in adipose tissues88, decreased hepatic endoplasmic reticulum and oxidative stress109,110, and increased beta-oxidation of lipids in the liver62”
From Metabolic messengers: FGF21 (2021) · cites this paper as [88]
In the citing paper
“clinical studies in patients with obesity and type 2 diabetes have found that FGF21-analogue administration markedly induces plasma adiponectin levels81,87–89”
From Metabolic messengers: FGF21 (2021) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
AIC model selection using Akaike weights
Wagenmakers, E.-J., & Farrell, S. (2004) · Psychonomic Bulletin & Review · doi:10.3758/bf03206482 · Cited by 2,684
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283
Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction
Elumalai, A., & Jain, S. K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061321 · Cited by 1,206
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Research works printed but not linked: 1
- Charles, 2016, A phase 1 study of BMS-986036 (pegylated FGF21) in healthy obese subjects, Hepatology, 64, 546A
Cited by
Sorted by citations
Harrison, S. A., Ruane, P. J., Freilich, B. L., Neff, G., Patil, R., Behling, C. A., Hu, C., Fong, E., de Temple, B., Tillman, E. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01425-3 · Cited by 368
Self-citationFlippo, K. H., & Potthoff, M. J. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00354-2 · Cited by 311
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 315
Harrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J., Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00272-8 · Cited by 276
Self-citationAn adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Lee, E., Korf, H., & Vidal‐Puig, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.024 · Cited by 235
Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 214
Self-citationNegi, C. K., Babica, P., Bajard, L., Vašků, J. B., & Tarantino, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 196
Harrison, S. A., Rolph, T., Knott, M., & Dubourg, J. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.034 · Cited by 179
Self-citationFGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance
Szczepańska, E., & Gietka‐Czernel, M. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1778-4159 · Cited by 155
New developments in the biology of fibroblast growth factors
Ornitz, D. M., & Itoh, N. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1549 · Cited by 147
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Noureddin, M., Rinella, M. E., Chalasani, N., Neff, G. W., Lucas, K. J., Rodriguez, M. E., Rudraraju, M., Patil, R., Behling, C. A., Burch, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502242 · Cited by 144
Self-citationMechanisms by Which Skeletal Muscle Myokines Ameliorate Insulin Resistance
Balakrishnan, R., & Thurmond, D. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094636 · Cited by 143
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Bhatt, D. L., Bays, H. E., Miller, M., Cain, J. E., Wasilewska, K., Andrawis, N. S., Parli, T., Feng, S., Sterling, L., Tseng, L., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02427-z · Cited by 121
Harrison, S. A., Ruane, P. J., Freilich, B., Neff, G., Patil, R., Behling, C., Hu, C., Shringarpure, R., de Temple, B., Fong, E., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100563 · Cited by 110
Self-citationHarrison, S. A., Frías, J. P., Lucas, K. J., Reiss, G. M., Neff, G. W., Bollepalli, S., Su, Y., Chan, D. C., Tillman, E. J., Moulton, A. W., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.02.022 · Cited by 117
Self-citationHenriksson, E., & Andersen, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601349 · Cited by 97
FGF19 and FGF21: In NASH we trust
Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 82
Horton, W. B., Love, K. M., Gregory, J. M., Liu, Z., & Barrett, E. J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00826.2024 · Cited by 95
FGF21 reverses MASH through coordinated actions on the CNS and liver
Rose, J. P., Morgan, D. A., Sullivan, A. I., Fu, X., Inigo-Vollmer, M., Burgess, S. C., Meyerholz, D. K., Rahmouni, K., & Potthoff, M. J. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.04.014 · Cited by 75
The potential function and clinical application of FGF21 in metabolic diseases
Chen, Z., Yang, L., Liu, Y., Huang, P., Song, H., & Zheng, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1089214 · Cited by 73
Rader, D. J., Maratos-Flier, E., Nguyen, A., Hom, D., Ferriere, M., Li, Y., Kompa, J., Martic, M., Hinder, M., Basson, C. T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab624 · Cited by 72
Jin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71
Current status and future perspectives of FGF21 analogues in clinical trials
Chui, Z. S. W., Shen, Q., & Xu, A. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.001 · Cited by 70
Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho
Aaldijk, A. S., Verzijl, C. R. C., Jonker, J. W., & Struik, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1150222 · Cited by 63
Yano, K., Yamaguchi, K., Seko, Y., Okishio, S., Ishiba, H., Tochiki, N., Takahashi, A., Kataoka, S., Okuda, K., Liu, Y. X., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00680-9 · Cited by 63
Ziqubu, K., Mazibuko-Mbeje, S. E., Mthembu, S. X. H., Mabhida, S. E., Jack, B. U., Nyambuya, T. M., Nkambule, B. B., Basson, A. K., Tiano, L., & Dludla, P. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032227 · Cited by 66
Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases
Li, X., Lu, W., Kharitonenkov, A., & Luo, Y. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13767 · Cited by 64
The Roles and Pharmacological Effects of FGF21 in Preventing Aging-Associated Metabolic Diseases
Yan, J., Nie, Y., Cao, J., Luo, M., Yan, M., Chen, Z., & He, B. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.655575 · Cited by 53
Adipokines as Clinically Relevant Therapeutic Targets in Obesity
Würfel, M., Blüher, M., Stümvoll, M., Ebert, T., Kovacs, P. L., Tönjes, A., & Breitfeld, J. (2023) · Biomedicines · doi:10.3390/biomedicines11051427 · Cited by 56
Multi-organ FGF21-FGFR1 signaling in metabolic health and disease
Kaur, N., Gare, S. R., Shen, J., Raja, R., Fonseka, O., & Liu, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.962561 · Cited by 49
Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
Kim, T. H., Hong, D.-G., & Yang, Y. M. (2021) · Biomedicines · doi:10.3390/biomedicines9121903 · Cited by 57
FGF-based drug discovery: advances and challenges
Chen, G., Chen, L., Li, X., & Mohammadi, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01125-w · Cited by 51
Hepatic hormone FGF21 and its analogues in clinical trials
Shao, W., & Jin, T. (2021) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2021.08.005 · Cited by 49
Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Besing, G.-L. K., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101718 · Cited by 49
Bridging systemic metabolic dysfunction and Alzheimer’s disease: the liver interface
Song, D., Yang, L., Yang, L.-L., Luo, Y., & Yao, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00849-6 · Cited by 53
Pharmacological Support for the Treatment of Obesity—Present and Future
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 54
Xiang, L., Wang, G., Zhuang, Y., Luo, L., Yan, J., Zhang, H., Li, X., Xie, C., He, Q., Peng, Y., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.006 · Cited by 49
Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fatty liver disease
Li, H., & Peng, Z. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114933 · Cited by 41
Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases
Dabravolski, S. A., Bezsonov, E. E., Baig, M. S., Попкова, Т. В., & Orekhov, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136949 · Cited by 44
Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies
Hua, S., Liu, Q., Li, J., Fan, M., Yan, K., & Ye, D. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09661-1 · Cited by 39
Emerging synthetic drugs for the treatment of liver cirrhosis
Fallowfield, J. A., Ramos, M. J., & Robertson, A. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1918099 · Cited by 39
Sommakia, S., Almaw, N. H., Lee, S. H., Ramadurai, D. K. A., Taleb, I., Kyriakopoulos, C. P., Stubben, C., Jing, L., Campbell, R. A., Alharethi, R. A., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008910 · Cited by 38
Fibroblast growth factor 21 in metabolic syndrome
Yang, M., Liu, C., Jiang, N., Liu, Y., Luo, S., Li, C., Zhao, H., Han, Y., Chen, W., Li, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1220426 · Cited by 40
Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis
Guo, X., Asthana, P., Zhai, L., Cheng, K. W., Gurung, S., Huang, J., Wu, J., Zhang, Y., Mahato, A. K., Saarma, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45452-3 · Cited by 44
The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM)
Al-Kuraishy, H. M., Al-Gareeb, A. I., Saad, H. M., & Batiha, G. E. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01255-4 · Cited by 39
Mitochondrial Stress and Mitokines: Therapeutic Perspectives for the Treatment of Metabolic Diseases
Zhang, B., Chang, J. Y., Lee, M. H., Ju, S. H., Yi, H., & Shong, M. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0115 · Cited by 39
Wong, C., Dash, A., Fredrickson, J. O., Lewin‐Koh, N., Chen, S., Yoshida, K. J., Liu, Y., Gutierrez, J., & Kunder, R. S. (2022) · Hepatology · doi:10.1002/hep.32742 · Cited by 36
Yadav, P., Khurana, A., Bhatti, J. S., Weiskirchen, R., & Navik, U. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106426 · Cited by 32
360-Degree Perspectives on Obesity
Cuciureanu, M. D., Caratașu, C.-C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., et al. (2023) · Medicina · doi:10.3390/medicina59061119 · Cited by 33
Retinopathy of prematurity: Metabolic risk factors
Fu, Z., Nilsson, A., Hellström, A., & Smith, L. E. H. (2022) · eLife · doi:10.7554/elife.80550 · Cited by 30
Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
Teng, T., Qiu, S., Zhao, Y., Zhao, S., Sun, D., Hou, L., Li, Y., Zhou, K., Yu, X., Yang, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147841 · Cited by 26
Jeon, H., Lee, A.-J., & Ha, K. (2022) · BioChip Journal · doi:10.1007/s13206-022-00057-0 · Cited by 26
Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
Zhang, Y., Wang, Y., & Liu, J. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.011 · Cited by 26
Puengel, T., & Tacke, F. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2230115 · Cited by 24
Use of FGF21 analogs for the treatment of metabolic disorders: a systematic review and meta-analysis
Carbonetti, M. P., Almeida‐Oliveira, F., & Majerowicz, D. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2022-0493 · Cited by 24
Giontella, A., Zagkos, L., Geybels, M. S., Larsson, S. C., Tzoulaki, I., Mantzoros, C. S., Andersen, B., Gill, D., & Cronjé, H. T. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155616 · Cited by 22
Cui, X., Sun, Q., & Wang, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1510322 · Cited by 24
Fibroblast growth factor 21: A “rheostat” for metabolic regulation?
She, Q.-Y., Bao, J., Wang, H.-Z., Liang, H., Huang, W., Wu, J., Zhong, Y.-W., Ling, H., Li, A., & Qin, S.-L. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155166 · Cited by 22
Tillman, E. J., Brock, W. J., & Rolph, T. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15725 · Cited by 22
Self-citationNielsen, M. H., Gillum, M. P., Vrang, N., Jelsing, J., Hansen, H. H., Feigh, M., & Oró, D. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00157.2022 · Cited by 20
Stanić, S., Bardová, K., Janovská, P., Rossmeisl, M., Kopecký, J., & Zouhar, P. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116042 · Cited by 20
AAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation
Wu, X., Yu, Y., Wang, M., Dai, D., Yin, J., Liu, W., Kong, D., Tang, S., Meng, M., Gao, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45383-z · Cited by 19
Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease
Chui, Z. S. W., Xue, Y., & Xu, A. (2024) · Medical Review · doi:10.1515/mr-2024-0007 · Cited by 21
Fibroblast growth factor 21 in dairy cows: current knowledge and potential relevance
Eder, K., Geßner, D. K., & Ringseis, R. (2021) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-021-00621-y · Cited by 18
Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 16
Wang, Q., Guo, Y., Yao, C., Zhang, K., Li, Q., Shan, C., Liu, P., Wang, M., Zhu, F., An, L., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202100768r · Cited by 16
Liu, L., Zhu, L., Cheng, Z., Sun, Y., Zhou, Y., & Cao, J. (2023) · Aging · doi:10.18632/aging.205041 · Cited by 15
Beneficial Gut Microbiome Remodeled During Intermittent Fasting in Humans
Larrick, J. W., Mendelsohn, A. R., & Larrick, J. W. (2021) · Rejuvenation Research · doi:10.1089/rej.2021.0025 · Cited by 18
Exploring endocrine FGFs - structures, functions and biomedical applications
Phan, P. (2024) · International Journal of Biochemistry and Molecular Biology · doi:10.62347/palk2137 · Cited by 16
Amatya, R., Lee, D.-H., Min, K. A., & Shin, M. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071963 · Cited by 13
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 15
Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
Luo, Y., Li, X., Ma, J., Abbruzzese, J. L., & Lu, W. (2021) · Cancers · doi:10.3390/cancers13040778 · Cited by 14
Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis
Suri, J. S., Borja, S., & Lim, J. K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i35.5129 · Cited by 14
White adipose tissue in type 2 diabetes and the effect of antidiabetic drugs
Zhao, Y., & Yue, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01678-9 · Cited by 13
Dorval, L., Knapp, B. I., Majekodunmi, O. A., Eliseeva, S. I., & Bidlack, J. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108858 · Cited by 13
Huai, Q., Zhu, C., Zhang, X., Dai, H., Li, X., & Wang, H. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000410 · Cited by 11
Imbalanced Skeletal Muscle Mitochondrial Proteostasis Causes Bone Loss
Jin, Z., Mao, Y., Guo, Q., Yin, Y., Kiram, A., Zhou, D., Yang, J., Zhou, Z., Xue, J., Feng, Z., et al. (2024) · Research · doi:10.34133/research.0465 · Cited by 13
Zhang, J., Li, Y., Liu, Y., Ma, N., Qian, S., Chen, Y., Duan, Y., Xiang, X., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01267-9 · Cited by 10
Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog
Sass‐Ørum, K., Tagmose, T. M., Olsen, J., Sjölander, A., Wahlund, P., Han, D., Vegge, A., Reedtz‐Runge, S., Wang, Z., Gao, X., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00391 · Cited by 11
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 11
Li, S., Zou, W.-Y., Zhou, Y., Li, W., Liao, W., Li, T., & Zhang, Z.-M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1594091 · Cited by 9
Research progress on the role of FGF21 in insulin resistance
Zhang, H., Zhu, R., Sun, Q., & Du, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1619462 · Cited by 10
Physical Exercise-Induced FGF-21 to Fight Obesity: An Update Review
Vecchiatto, B., de Castro, T. L., Muller, C. R., Azevedo‐Martins, A. K., & Evangelista, F. S. (2022) · Obesities · doi:10.3390/obesities2040031 · Cited by 9
Fibroblast growth factor 21 and dietary interventions: what we know and what we need to know next
Jin, T. (2022) · Medical Review · doi:10.1515/mr-2022-0019 · Cited by 8
Nie, Z., Xu, J., Liu, Y., Cao, Q., Qiu, X., Su, Y., & Han, S. (2025) · International Journal of Endocrinology · doi:10.1155/ije/9943228 · Cited by 8
Defective FGFR1 Signaling Disrupts Glucose Regulation: Evidence From Humans With FGFR1 Mutations
Stamou, M. I., Chiu, C. J., Jadhav, S. V., Lopes, V. F., Salnikov, K. B., Plummer, L., Lippincott, M. F., Lee, H., Seminara, S. B., & Balasubramanian, R. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae118 · Cited by 7
Sostre‐Colón, J., Gavin, M. J., Santoleri, D., & Titchenell, P. M. (2022) · Endocrinology · doi:10.1210/endocr/bqac035 · Cited by 7
Functions of FGF21 and its role in cardiac hypertrophy
Chen, L., Gao, M., Ong, S., & Gong, G. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.03.007 · Cited by 7
Brodosi, L., Petroni, M. L., & Marchesini, G. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2208746 · Cited by 7
Kinne, A. S., Tillman, E. J., Abdeen, S. J., Johnson, D. E., Parmer, E. S., Hurst, J. P., de Temple, B., Rinker, S. D., Rolph, T., & Bowsher, R. R. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115402 · Cited by 6
Self-citationPotential of FGF21 in type 2 diabetes mellitus treatment based on untargeted metabolomics
Li, S., Song, Z., Fan, C., Zhang, W., Ma, T., Li, X., Zhang, Q., Zhao, M., Yu, T., & Li, S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116306 · Cited by 6
Ott, F., Körner, C., Werner, K., Gericke, M. T., Liebscher, I., Lobsien, D., Radrezza, S., Shevchenko, A., Hofmann, U., Kratzsch, J., et al. (2022) · Cells · doi:10.3390/cells11101680 · Cited by 6
Tseng, C.-M. L., Balic, K., Charlton, R. W., Margalit, M., Mansbach, H., & Savić, R. M. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3046 · Cited by 6
Kamrul-Hasan, A. B. M., Borozan, S., Jena, S., Nagendra, L., Dutta, D., Bhattacharya, S., Islam, M. S., & Pappachan, J. M. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.110709 · Cited by 6
Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach
Li, X., Rao, Z., Hu, W., Lu, W., & Luo, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13861 · Cited by 6
Matsui, M., Kosaki, K., Myoenzono, K., Yoshikawa, T., Park, J., Kuro‐o, M., & Maeda, S. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1902-3872 · Cited by 5
Pedersen, A. K. N., Hage, C., Jessen, N., Mellbin, L., & Bjerre, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111738 · Cited by 4
Norlin, J., Dermit, M., Sidiropoulos, N., Galsgaard, E. D., Hansen, H. H., Feigh, M., Veidal, S. S., Latta, M. R., Henriksson, E., & Andersen, B. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331665 · Cited by 3
Dahl, K., Friedrichsen, M. H., Ribel‐Madsen, R., Hansen, J. S., Clausen, J. O., Axelsen, M. B., Palle, M. S., Lippert, S. L., Björkdahl, O., Toubro, S., et al. (2025) · Clinical and Translational Science · doi:10.1111/cts.70435 · Cited by 3
Szczepańska, E., Glinicki, P., Zgliczyński, W., Slowinska-Srzednicka, J., Jastrzębska, H., & Gietka‐Czernel, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.900034 · Cited by 3
Metadata
- Authors
- Kaufman, A., Abuqayyas, L., Denney, W. S., Tillman, E. J., & Rolph, T.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Rolph, Tim
- Venue
- Cell Reports Medicine
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 1
- Issue
- 4
- Pages
- 100057
- ISSN
- 2666-3791 (ISSN-L)
- PMC
- PMC7659583
- OpenAlex
- W3044370932
- Cited by
- 131
- References
- 82
- Citations by year
- 2026: 12 · 2025: 24 · 2024: 25 · 2023: 21 · 2022: 26 · 2021: 19 · 2020: 4
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cell Reports Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- FGF21 analogs, type 2 diabetes, insulin sensitivity, lipid metabolism, pharmacodynamics, pharmacokinetics, lipoprotein profile, triglycerides, non-HDL cholesterol, apolipoprotein B, apolipoprotein C-III, tolerability
- MeSH terms
- Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Insulin, Insulin Resistance, Lipids, Male, Middle Aged, Obesity, Recombinant Fusion Proteins, Triglycerides, United States, Placebo Effect, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
